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 An estimation of the incidence and demographic picture of the major hemoglobinopathies in
Belgium has been approached through a confidential inquiry sent to 228 pediatric and adult
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hematological departments. Forty-two percent of responses showed that 417 patients are known in
Belgium: 83% with sickle cell disease, 13% with b-thalassemia (b-thal) major, 2% with b-thal
intermedia, and 1% with Hb H disease. Twenty-five percent of the sickle cell disease patients and
54% of those suffering from a b-thal major were older than 20 years. Three hospitals ensure the
follow-up of 70% of the patients and are situated in Brussels, Belgium; a follow-up of less than
20 patients was reported at 21 centers. These results confirm that sickle cell disease is the major
hemoglobinopathy in Belgium; it concerns mostly pediatricians but adult hematologists are also
confronted with these pathologies. Therefore, it is necessary to implement integrated programs of
prevention and treatment.
Keywords Sickle cell disease/disorder(s), Thalassemia, Incidence, Europe
INTRODUCTION
Hemoglobinopathies are recessively inherited blood disorders; they
occur more frequently in populations where malaria was or is endemic (1).
This is the reason why these disorders are rarely encountered in indigenous
North and West European populations. Nowadays, European populations
are a mixture of individuals from various ethnic origins but the number of
individuals originating from a country at-risk for a hemoglobinopathy is
increasing (2). In this context, global health care has been implemented in
the United Kingdom and France, where hemoglobinopathies are encoun-
tered with a high incidence (3,4); it includes neonatal and, in the UK, ante-
natal national prevention programs.
In The Netherlands, many publications have shown that hemoglobinop-
athies are a serious global health problem in that country, where a high level
of immigration is reported (5–7). Belgium has the same need for a preven-
tion policy towards hemoglobinopathies. Estimating prevalence of carriers
and annual affected births can be obtained for Belgium and were recently
published (2), but the real incidence of these disorders has only been
reported for Brussels since a systematic neonatal screening for hemoglobin-
opathies has only been conducted in that city since 1994 (8). The purpose of
the present study was to estimate the number of patients suffering from a
major hemoglobinopathy, who have regular follow-up examinations, and
thus to evaluate the need for the implementation of an integrated strategy
for hemoglobinopathies prevention, diagnosis and treatment in Belgium.
MATERIALS AND METHODS
In November 2005 and in May 2006, all the Belgian adult internal
medicine and pediatric departments (n = 228) received a letter explaining
the health problem of hemoglobinopathies and asking for a report on their
patients suffering from a major hemoglobinopathy. They were asked to
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The anonymous inquiry asked for the birth date and sex of each patient
regularly followed and suffering from a sickle cell disorder [i.e., Hb SS, Hb
SC, Hb S/β-thalassemia (β-thal) or another type], a β-thal major or interme-
dia, or a Hb H disease. It also asked if a specific therapy was given to their
patients (hydroxyurea, transfusion, or bone marrow transplant), and if
their geographic origin was known.
RESULTS
Forty-two percent (96/228) responses were received. Except for the
province of Luxembourg (where one response from five centers was
received), more than 37% responses were received from each of the other
eight Belgian provinces. No patients, less than five patients and between
five and 20 patients were followed in 71, 11 and 10 departments, respec-
tively. Four centers reported more than 20 patients. After discarding double
registrations, 417 patients suffering from a severe hemoglobinopathy were
reported (Table 1). Of these, 346 were sickle cell disease patients, 56 were
affected by a β-thal major, 10 by a β-thal intermedia and five by Hb H
disease. The sickle cell disease group of patients was composed of 319 Hb
SS, 13 Hb SC disease, 13 Hb S/β-thal, and one Hb SD patient. Three
Brussels centers ensure the follow-up of 293/417 patients (70%).
The age range within the two major groups of patients, i.e., sickle cell
disease and β-thal major, is represented in Figure 1. The majority (75%) of
sickle cell disease patients were younger than 21 years old, while more than
a half (54%) of the patients suffering from a β-thal major, were older than
20 years. The sex ratio was 1:1.
No specific therapy was given to 15% of the Hb SS (46/316; median age
6 vs. 14 years old for those receiving a specific therapy) and Hb S/β-thal
cases (2/13), 46% of the Hb SC disease cases (6/13; median age 3 vs.
17 years old for those receiving a specific therapy), 56% of the β-thal
intermedia (5/9; median age 9 vs. 34 years old for those receiving a specific
TABLE 1 Distribution of Patients by Hemoglobinopathy
Age (years)
Hemoglobin Disorders n Median Range
Hb SS 319 13.0 1–47
Hb SC 13  7.0 1–53
Hb S/β-thal 13 15.0 5–49
Hb SD 1 19.0 –
β-Thal major 56 22.0 1–42
β-Thal intermedia 10 12.5 2–37
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therapy) and 100% of the Hb H disease cases. All patients suffering from a
β-thal major received a specific treatment.
The geographic ancestry origin was reported for 142 patients. The main
geographic ancestry origin was Sub-Saharan Africa for sickle cell disease
patients (81/93; 88%), the Mediterranean Basin for the patients affected by
a β-thal major or intermedia (37/45; 82%), and Asia for Hb H disease
patients (5/5; 100%).
DISCUSSION
With a 42% response and a well distributed level of response within
each of the nine Belgian provinces, and considering a certain level of
underestimation, it might be established that in a Belgian population of
around 10 millions inhabitants, at least 500 patients are being followed for a
hemoglobinopathy and that there is an increasing prominence of sickle cell
disorders. The Belgian Cystic Fibrosis Registry reported 860 living patients
in 2003, implying that hemoglobinopathies are now as significant as cystic
fibrosis in their contribution to inherited disorders in this country; the
same conclusion was previously given for all of Europe (9,10).
These results are concordant with those obtained through the system-
atic neonatal screening for hemoglobinopathies in Brussels, as it had
been demonstrated that in a population of more than 100,000 newborns
screened, the incidence of sickle cell disorders was around 1:2,000, of β-thal
major was around 1:20,000, and of Hb H disease was around 1:40,000 (8).
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It is also interesting to find that the same picture was observed in The
Netherlands in 2002: among 16 million inhabitants, at least 700 patients were
followed for a sickle cell disorder and 100 for a β-thal major anomaly (7).
Recent publications have also confirmed the prominence of sickle cell dis-
orders in the UK (2) and France (4,11). One must be aware that these num-
bers will probably continue to increase in North and West European
countries since most migrants are young, have a high birth rate and fre-
quently, consanguineous marriages; on the other hand, a falling general
birth rate compared to European indigenous populations will probably
contribute to a decrease in the incidence of hemoglobinopathies in South-
ern Europe (2).
Our results demonstrated that with a median age of 13 years old, sickle
cell disease concerned mostly pediatricians. However, with 25% of patients
older than 21 years and the increase in life expectancy, it is also of impor-
tance to take into account adult patients, and more specifically, pregnancy.
In the Dutch inquiry, it was reported that almost half the patients
affected with sickle cell disease were older than 15 years. That difference
with our results might be attributed to an increase of immigration in the
last few years in The Netherlands (12). Another explanation might be
related to the fact that a systematic neonatal screening for hemoglobino-
pathies was implemented only at the start of 2007 in The Netherlands.
Indeed, among the 96 sickle cell disease patients reported by the Brussels
centers and who are younger than 10 years of age, 80 were detected by
the Brussels systematic neonatal screening, which implies a very early
diagnosis and follow-up.
Another crucial aspect is the variable number of patients followed in a
center. The Dutch inquiry revealed the same picture: patients are concen-
trated in large cities (7). The heterogeneous distribution of patients with a
rare disease should encourage the development of a partnership with health
care professionals and patients’ associations. Belgium has seen the creation
of a health care professional group within the Belgian hematological society
(http://www.bhs.be/). The aims are mainly focused on national recom-
mendations for prevention, diagnosis and management of hemoglobinopa-
thies, and the creation of a patient database.
Various strategies have been applied in Europe (2), but there is often
still a lack of awareness among health authorities. It is probably time to
work together and to integrate the existing European dedicated networks
like the new “EuroMediterranean Network of Research Centres Conducting
Molecular and Clinical Research of Thalassaemia and Related Haemoglo-
binopathies” (http://www.ithanet.eu) and the “European Network for Rare
and Congenital Anaemias” (http://www.enerca.org).
The main geographic origins of the patients were those expected for

























284 B. Gulbis et al.
origins who are at-risk for combined hemoglobinopathies. Some ethnic
groups are poorly represented in this country and there might be an almost
complete lack of awareness among health care workers about specific
hemoglobinopathies.
CONCLUSIONS
Population movement within Europe or from other countries where
people are at risk for hemoglobin disorders have increased during these
last few decades. Europe, from the North to the West, is facing more and
more affected births, and sickle cell disorders represent the major part of
the hemoglobinopathies encountered; to date, more affected children are
born in the immigration areas of Northern Europe than in the original
endemic countries of Southern Europe. Although rare, these disorders now
represent a significant health problem in Europe, and epidemiological data
are good for assessing needed health care.
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